A TwoPart, Phase 1, Randomized, SingleBlind, PlaceboControlled, SingleDose, DoseEscalation Study of Subcutaneous and Intravenous Administration of IL31 mAb (antiInterleukin 31 Monoclonal Antibody; BMS981164) in Healthy Subjects and Adult Subjects with Atopic Dermatitis

Trial Profile

A TwoPart, Phase 1, Randomized, SingleBlind, PlaceboControlled, SingleDose, DoseEscalation Study of Subcutaneous and Intravenous Administration of IL31 mAb (antiInterleukin 31 Monoclonal Antibody; BMS981164) in Healthy Subjects and Adult Subjects with Atopic Dermatitis

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Interleukin 31 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms Atopic Dermatitis
  • Most Recent Events

    • 15 Apr 2015 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network.
    • 07 Jun 2014 Planned number of patients changed from 32 to 42 as reported by United Kingdom Clinical Research Network.
    • 16 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top